Compare J B Hunt Transport Services Inc (JBHT) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
J B Hunt Transport Services Inc vs Summit Therapeutics Inc — how do they compare? J B Hunt Transport Services Inc trades at $265.38 (market cap $24.92B), while Summit Therapeutics Inc trades at $15.1 (market cap $12.06B). The key difference: J B Hunt Transport Services Inc is far larger — about 2.1× Summit Therapeutics Inc's market cap, and J B Hunt Transport Services Inc pays a 0.68% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| JBHT | SMMT | |
|---|---|---|
Market Cap | $24.92B | $12.06B |
Sector | Industrials | Health |
52-Week High | $298.41 | $26.98 |
52-Week Low | $130.65 | $12.55 |
Enterprise Value | $26.06B | $11.39B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBHT trades at $275.5, up 3.52% today, with a bearish technical signal but strong analyst consensus. The company reported revenue of $12.0B in 2025, with net income of $598.28M and a 5.31% net margin. Recent earnings have consistently beaten estimates, and the company announced a $0.45 dividend payable in August 2026. Cash flow from operations remains robust at $1.68B in 2025, though net cash flow was slightly negative.
The outlook is positive with a consensus price target of $299.82, implying 8.8% upside. Risks include competitive pressures and macroeconomic volatility, but strong institutional ownership and a buy rating from 57.8% of analysts support a favorable view. The stock's valuation multiples are elevated, but earnings growth and intermodal demand recovery provide catalysts.
Summit Therapeutics (SMMT) trades at $15.23, up 2.42% today, with a bullish technical signal and strong analyst consensus. The stock shows mixed earnings performance but benefits from positive news on ivonescimab's regulatory progress and clinical expansions. Despite negative profitability metrics, investor sentiment is buoyed by a high price target of $38.00 and recent partnership announcements in cancer drug development.
Outlook hinges on FDA approval for ivonescimab by November 2026, offering significant upside if successful. Risks include cash burn, ongoing losses, and fiduciary investigations. The stock presents a high-risk, high-reward opportunity for speculative investors betting on clinical successes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About J B Hunt Transport Services Inc
J.B. Hunt Transport Services ranks among the top surface transportation companies in North America by revenue. Its primary operating segments are intermodal delivery, which uses the Class I rail carriers for the underlying line-haul movement of its owned containers (45% of sales in 2021).
Read more on JBHT →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
